SHINPOONG PHARMACEUTICAL CO.,LTD

019170 KRX Pharmaceuticals Pharmaceuticals
KOSPI
₩10,020.00
+1.73%
Delayed · cached 15 min

Fair value analysis

019170
SHINPOONG PHARMACEUTICAL CO.,LTD
Pharmaceuticals›Pharmaceuticals
₩10,020.00
Close used for this calculation
₩3,862.36Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
27/100
Profitability4/25
Returns0/25
Balance Sheet21/25
Efficiency2/25
Growth0/25
Weak
Quality radar
27Prof.4/25Ret.0/25Eff.2/25B.Sht21/25Growth0/25

Consensus fair value

₩3,862.36
Above FV
▼ -61.5% against the close used
Model range ₩211.19 – ₩5,293.84
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₩211.19Fair value₩3,862.36Bull₩5,293.84
FairClose
52-week traded range
52W low ₩7,210.0052W high ₩15,690.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

SHINPOONG PHARMACEUTICAL CO.,LTD closed at ₩10,020.00, 159.4% above the consensus fair value of ₩3,862.36 drawn from 7 valuation models.

Financial DNA score 27/100 — Weak. P/E of 58.3x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₩5,293.84
-47.2%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩4,603.24
-54.1%
√(22.5 × EPS × BVPS)
EPS=172, BVPS=5475.41 · outside Graham range (P/E 58.3, P/B 1.8) — asset-light, treat as a rough floor
P/E Fair Value
₩3,440.00
-65.7%
EPS × 20x (sector P/E)
EPS=172, Sector P/E=20x
EV/EBITDA
₩2,078.17
-79.3%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=14.26B
Book Value (P/B)
₩211.19
-97.9%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=5475.41, ROE=3.3%, g=3%, r=10%
Reverse DCF
₩10,020.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 21.6% | Historical: 0%
Margin of Safety
₩3,334.27
-66.7%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=4445.69, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.